LD

Liptan Das

Active Director Director DIN 10614987
DIN 10614987 First appointment May 2024 Primary industry Software
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Liptan Das

Data last updated:

Liptan Das is a Director at Probe International Clinical Research Private Limited (since 2024). The company operates in Software.

DIN 10614987
Primary Designation Director
Industry Software
First Appointment 02 May 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director02 May 20242024Active

Directorship timeline

Open interactive timeline →
Probe International Clinical Research Private Limited
Premium access

Shareholding and investment profile for Liptan Das

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Liptan Das

Liptan Das currently holds 1 directorship: Probe International Clinical Research Private Limited (Director, since 02 May 2024).

Liptan Das was first appointed on 02 May 2024 as Director at Probe International Clinical Research Private Limited.

The current boards of Liptan Das's companies include Amit Hazra (Probe International Clinical Research Private Limited), Bijoy Das (Probe International Clinical Research Private Limited), Soumyadip Samanta (Probe International Clinical Research Private Limited), Subhrojyoti Bhowmick (Probe International Clinical Research Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available